What the business is, and whether it's a good one at a fair price.
Develops a clinical-stage pharmaceutical pipeline focused on oncology, immunology, and dermatology-autoimmune diseases, with two priority programs — SCD-153 (topical itaconate for alopecia areata with Johns Hopkins) and SBO-154 (a MUC1-targeting MMAE antibody-drug conjugate) — in Phase 1 trials running in the US, Australia and India. FY26 reported revenue of Rs 1,879.17 cr came almost entirely from a one-time Priority Review Voucher (PRV) granted by the US FDA upon approval of Sezaby, a treatment for neonatal seizures, and subsequently sold for USD 195 million in April 2026; underlying pharmaceutical R&D activities generated only Rs 3,915 lakhs in regular revenue. Earlier licensed products include Xelpros, Elepsia, Taclantis, PDP-716 and SDN-037, although the November 2019 China licence with CMS Bridging was terminated in June 2026 and the PDP-716 NDA received a Complete Response Letter in May 2026 over manufacturing-site inspection findings. The portfolio also includes preclinical work on targeted oncology and synthetic lethality, an out-licensed CML asset (Vodobatinib) now effectively in limbo, and SCO-155 advanced via a NewCo partnership template (Tiller Therapeutics). Headcount was cut from 400+ to ~250 in the cost optimisation programme, with management citing $10 million in annual fixed-cost savings, and approximately Rs 150 crore was raised upfront from a Rs 600 crore preferential warrant issue to the promoter group. Operating cost shape is dominated by employees (6.3% of revenue) and other opex (7.4%), with materials at just 1.3%, consistent with a clinical R&D business.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from SUN PHARMA ADV.RES.CO.LTD's filed financials and exchange disclosures
SUN PHARMA ADV.RES.CO.LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SPARC.
Yes. Over the trailing twelve months SUN PHARMA ADV.RES.CO.LTD reported a net profit of ₹1,584 Cr on revenue of ₹1,909 Cr.
Not in the latest reported year — SUN PHARMA ADV.RES.CO.LTD's dividend payout for FY26 was nil.
No. Debt stands at 0.42× equity, and it carries net debt of ₹555 Cr. That is lower than 23% of its 171 Pharmaceuticals peers.
On trailing P/E, SUN PHARMA ADV.RES.CO.LTD ranks 6 of 169 in Pharmaceuticals — cheaper than 97% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session SUN PHARMA ADV.RES.CO.LTD moves 1.44% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by SUN PHARMA ADV.RES.CO.LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
